COVID-19 has resulted in fewer visits to ophthalmology practices but Bayer AG's first-quarter 2021 results show that that the pandemic has not hurt the dominant position of the company's blockbuster eye drug Eylea.
Japan Helps Bayer’s Eylea Sales To Sparkle
Strong Quarter For German Major
Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.
